Lyell Immunopharma, Inc. (LYEL)
12.09
-0.79
(-6.13%)
USD |
NASDAQ |
Sep 10, 14:19
Lyell Immunopharma Debt to Equity Ratio : 0.1993 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1993 |
| March 31, 2026 | 0.1785 |
| December 31, 2025 | 0.2055 |
| September 30, 2025 | 0.1613 |
| June 30, 2025 | 0.1559 |
| March 31, 2025 | 0.1696 |
| December 31, 2024 | 0.154 |
| September 30, 2024 | 0.1104 |
| June 30, 2024 | 0.1063 |
| March 31, 2024 | 0.1025 |
| December 31, 2023 | 0.0964 |
| September 30, 2023 | 0.0927 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0897 |
| March 31, 2023 | 0.085 |
| December 31, 2022 | 0.0813 |
| September 30, 2022 | 0.0788 |
| June 30, 2022 | 0.0761 |
| March 31, 2022 | 0.0766 |
| December 31, 2021 | 0.0729 |
| September 30, 2021 | 0.0681 |
| June 30, 2021 | 0.0621 |
| March 31, 2021 | -3.207 |
| December 31, 2020 | -3.642 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 311.15M |
| Total Liabilities (Quarterly) | 77.34M |
| Shareholders Equity (Quarterly) | 233.82M |
| Current Ratio | 5.356 |
| Net Debt Paydown Yield | 0.64% |